Comfort of Patients Under Non Invasive Ventilation According to the Mask

NCT ID: NCT06212180

Last Updated: 2024-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A sub-nasal mask with a skirt that fits the nostrils and with a dedicated port for the nasogastric tube has recently been introduced. This interface has never been compared to nasal-oral masks. We hypothesise that such a sub-nasal mask increases comfort compared to a conventional naso-oral mask. The primary objective is to compare the comfort of the sub-nasal mask with that of a standard naso-oral mask.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-invasive ventilation (NIV) is a first-line treatment for many conditions encountered in the ICU. This technique requires training of heath professionals, appropriate equipment, optimisation of ventilator settings and good cooperation from the patient. Indeed, NIV failures lead ton invasive mechanical ventilation, thus increasing morbidity and mortality. These failures are favoured by the patient's poor tolerance to NIV. The success of the treatment depends greatly on the patient's compliance and comfort. The choice of the mask is therefore essential. There are different types of interface, such as the full-face helmet, the face mask, the nasal-oral mask or the nasal mask. The nasal-oral mask rmains the most commonly used interface. Recommendations emphasise the importance of choosing a mask that is the right size and best tolerated by the patient. Despite benefits of NIV, there are a number of potential complications: skin lesions at pressure points, particulaly at the nasal bridge, gastric distension, barotrauma, haemodynamic effects of positive presure ventilation, claustrophobia, anxiety, difficulty in speaking and eating, dry eyes, patient-ventilator asynchrony. Some of these complications depend on the type of mask used. a sub-nasal mask with a skirt that fits the nostrils and a dedicated port for the nasogastric tube has recently been introduced. To our knowledge, this interface has never been compared to commercially avaible nasal-oral masks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Exacerbation Hypercapnia Hypoventilation Obesity Syndrome Acute Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mask

patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

oronasal mask or subnasal mask

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Indication of NIV, carried out by the physicians in charge of the patient, among the following:

* COPD exacerbation
* Hydrostatic acute pulmonary edema
* Acute Chest Syndrome with Hypercapnia in Sickle Cell Patients
* Post-extubation, planned in a patient at risk or recovering from extubation failure
* Hypoventilation-obesity syndrome

Exclusion Criteria

Formal contraindication to NIV among:

* Indication for orotracheal intubation at the outset
* Non-cooperative, agitated, opponent of the technique
* Coma
* Respiratory exhaustion
* Shock, severe ventricular arrhythmias, immediate aftermath of cardiac arrest
* Undrained pneumothorax, blowing chest wound
* Upper airway obstruction (except sleep apnea, laryngotracheomalacia)
* Uncontrollable vomiting
* Upper gastrointestinal bleeding
* Measure of protection of justice
* Facial deformity
* Dying or palliative care patient
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christophe CARPENTIER, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Henri Mondor - Réanimation/ Unité de Surveillance Continue

Créteil, , France

Site Status

CHU Bicêtre - Unité de Soins Intensifs Pneumologique

Le Kremlin-Bicêtre, , France

Site Status

CHU Bicêtre - USC

Le Kremlin-Bicêtre, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christophe CARPENTIER, MD

Role: CONTACT

0145217138 ext. 33

Tai PHAM, MD

Role: CONTACT

0145217138 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Armand Mekontso Dessap, MD

Role: primary

Laurent SAVALE, MD

Role: primary

Christophe CARPENTIER, MD

Role: primary

0145217138 ext. 33

Tai PHAM, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A02093-42

Identifier Type: OTHER

Identifier Source: secondary_id

APHP231673

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.